Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency

Summary

Fibrinogen is a plasma glycoprotein mainly synthesised by hepatocytes and circulating as a 340-kDa hexamer consisting of two sets of three different polypeptide chains (Aα, Bβ, and γ, encoded by the FGA, FGB, and FGG gene, respectively). Congenital afibrinogenaemia and hypofibrinogenaemia are rare bleeding disorders characterised by abnormally low levels of functional and immunoreactive fibrinogen in plasma, associated with haemorrhagic manifestations of variable severity. While afibrinogenaemia is caused by mutations in the homozygous or compound heterozygous state in one of the three fibrinogen genes, hypofibrinogenaemia is generally due to heterozygous mutations, and is usually characterised by a milder phenotype. The mutational spectrum of these quantitative fibrinogen disorders includes large deletions, point mutations causing premature termination codons, and missense mutations often affecting fibrinogen assembly and/or secretion. Here we report the clinical and molecular characterisation of 13 unrelated afibrinogenaemic and eight hypofibrino - genaemic patients, leading to the identification of 17 different mutations (10 hitherto unknown). All the newly-identified missense and splicing mutations were in vitro expressed to verify their pathogenic role. Our data increase the number of mutations causing quantitative fibrinogen deficiencies by about 7 %. The high number of private mutations identified in the analysed probands indicates that the full mutational screening of the three fibrinogen genes is still required for molecular diagnosis.

Keywords

Afibrinogenaemia - hypofibrinogenaemia - mutational screening - expression experiments

• References

• 1 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-1904.
• 2 Weisel JW, Litvinov RI. Mechanisms of fibrin polymerization and clinical implications. Blood 2013; 121: 1712-1719.
• 3 Podolnikova NP, Yakovlev S, Yakubenko VP. et al. The interaction of integrin aIIbβ3 with fibrin occurs through multiple binding sites in the aIIb β-propeller domain. J Biol Chem 2014; 289: 2371-2383.
• 4 Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann NY Acad Sci 2001; 936: 480-495.
• 5 Huang S, Mulvihill ER, Farrell DH. et al. Biosynthesis of human fibrinogen. Subunit interactions and potential intermediates in the assembly. J Biol Chem 1993; 268: 8919-8926.
• 6 Zhang JZ, Redman CM. Assembly and secretion of fibrinogen. Involvement of amino-terminal domains in dimer formation. J Biol Chem 1996; 271: 12674-12680.
• 7 Zhang JZ, Redman CM. Fibrinogen assembly and secretion. Role of intrachain disulfide loops. J Biol Chem 1996; 271: 30083-30088.
• 8 Kollman JM, Pandi L, Sawaya MR. et al. Crystal structure of human fibrinogen. Biochemistry 2009; 48: 3877-3886.
• 9 Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 10: 2115-2129.
• 10 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39: 585-595.
• 11 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-1252.
• 12 Cattaneo M, Bettega D, Lombardi R. et al. Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. Br J Haematol 1992; 82: 388-390.
• 13 Spena S, Duga S, Asselta R. et al. Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen Bbeta-chain gene causing activation of cryptic splice sites. Blood 2002; 100: 4478-4484.
• 14 Plate M, Asselta R, Spena S. et al. Congenital hypofibrinogenemia: characterization of two missense mutations affecting fibrinogen assembly and secretion. Blood Cells Mol Dis 2008; 41: 292-297.
• 15 Puls F, Goldschmidt I, Bantel H. et al. Autophagy-enhancing drug carbamaze-pine diminishes hepatocellular death in fibrinogen storage disease. J Hepatol 2013; 59: 626-630.
• 16 Asselta R, Spena S, Duga S. et al. Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. Haematologica 2002; 87: 855-859.
• 17 Neerman-Arbez M, de Moerloose P, Honsberger A. et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes. Hum Genet 2001; 108: 237-240.
• 18 Wyatt J, Brennan SO, May S. et al. Hypofibrinogenaemia with compound heterozygosity for two gamma chain mutations - gamma 82 Ala>Gly and an intron two GT>AT splice site mutation. Thromb Haemost 2000; 84: 449-452.
• 19 Asselta R, Duga S, Spena S. et al. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen Aalpha-chain gene are not associated with the decay of the mutant mRNAs. Blood 2001; 98: 3685-3692.
• 20 Hanss M, Pouymayou C, Blouch MT. et al. The natural occurrence of human fibrinogen variants disrupting inter-chain disulfide bonds (A{alpha}Cys36Gly, A{alpha}Cys36Arg and A{alpha}Cys45Tyr) confirms the role of N-terminal A{alpha} disulfide bonds in protein assembly and secretion. Haematologica 2011; 96: 1226-1230.
• 21 Brennan SO, Maghzal G, Shneider BL. et al. Novel fibrinogen gamma375 Arg>Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36: 652-658.
• 22 Attanasio C, David A, Neerman-Arbez M. Outcome of donor splice site mutations accounting for congenital afibrinogenemia reflects order of intron removal in the fibrinogen alpha gene (FGA). Blood 2003; 101: 1851-1856.
• 23 Asselta R, Duga S, Spena S. et al. Missense or splicing mutation? The case of a fibrinogen Bbeta-chain mutation causing severe hypofibrinogenemia. Blood 2004; 103: 3051-3054.
• 24 Zucker M, Rosenberg N, Peretz H. et al. Point mutations regarded as missense mutations cause splicing defects in the factor XI gene. J Thromb Haemost 2011; 9: 1977-1984.
• 25 Duga S, Asselta R. Mutations in disguise. J Thromb Haemost 2011; 9: 1973-1976.
• 26 Spena S, Asselta R, Platé M. et al. Pseudo-exon activation caused by a deep-in-tronic mutation in the fibrinogen gamma-chain gene as a novel mechanism for congenital afibrinogenaemia. Br J Haematol 2007; 139: 128-132.
• 27 Plate M, Duga S, Castaman G. et al. Recurrence of the deep-intronic’ FGG IVS6-320A>T mutation causing quantitative fibrinogen deficiency in the Italian population of Veneto. Blood Coagul Fibrinolysis 2009; 20: 381-384.
• 28 Dear A, Daly J, Brennan SO. et al. An intronic mutation within FGB (IVS1+2076 a-->g) is associated with afibrinogenemia and recurrent transient ischemic attacks. J Thromb Haemost 2006; 4: 471-472.
• 29 Melamud E, Moult J. Stochastic noise in splicing machinery. Nucleic Acids Res 2009; 37: 4873-4886.
• 30 Neerman-Arbez M, Germanos-Haddad M, Tzanidakis K. et al. Expression and analysis of a split premature termination codon in FGG responsible for congenital afibrinogenemia: escape from RNA surveillance mechanisms in transfected cells. Blood 2004; 104: 3618-3623.
• 31 Soya K, Takezawa Y, Okumura N. et al. Nonsense-mediated mRNA decay was demonstrated in two hypofibrinogenemias caused by heterozygous nonsense mutations of FGG, Shizuoka III and Kanazawa II. Thromb Res 2013; 132: 465-470